Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.29 Insider Own39.09% Shs Outstand80.50M Perf Week0.88%
Market Cap1.30B Forward P/E- EPS next Y-1.73 Insider Trans-0.34% Shs Float49.22M Perf Month13.66%
Income-194.94M PEG- EPS next Q-0.56 Inst Own63.65% Short Float10.86% Perf Quarter32.84%
Sales163.36M P/S7.94 EPS this Y4.89% Inst Trans1.37% Short Ratio9.47 Perf Half Y6.08%
Book/sh4.36 P/B3.68 EPS next Y20.47% ROA-42.03% Short Interest5.34M Perf Year9.40%
Cash/sh3.79 P/C4.24 EPS next 5Y21.00% ROE-56.29% 52W Range9.90 - 17.69 Perf YTD-0.43%
Dividend Est.- P/FCF- EPS past 5Y4.07% ROI-52.22% 52W High-9.21% Beta0.37
Dividend TTM- Quick Ratio3.59 Sales past 5Y51.62% Gross Margin93.69% 52W Low62.22% ATR (14)0.72
Dividend Ex-Date- Current Ratio3.80 EPS Y/Y TTM10.00% Oper. Margin-129.14% RSI (14)59.06 Volatility3.20% 4.99%
Employees355 Debt/Eq0.07 Sales Y/Y TTM21.88% Profit Margin-119.33% Recom1.55 Target Price22.82
Option/ShortYes / Yes LT Debt/Eq0.06 EPS Q/Q9.42% Payout- Rel Volume0.51 Prev Close15.75
Sales Surprise5.14% EPS Surprise6.91% Sales Q/Q32.88% EarningsFeb 06 BMO Avg Volume564.08K Price16.06
SMA207.57% SMA505.78% SMA20016.95% Trades Volume288,797 Change1.97%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Resumed JP Morgan Neutral $14
Oct-30-23Upgrade Piper Sandler Neutral → Overweight $23
Aug-10-23Upgrade Stifel Hold → Buy $14 → $20
Jan-04-23Upgrade Guggenheim Neutral → Buy $22
Aug-29-22Initiated Cowen Outperform $25
Aug-05-22Upgrade JMP Securities Mkt Perform → Mkt Outperform $23
Feb-28-22Downgrade Barclays Equal Weight → Underweight $11 → $6
Nov-08-21Downgrade Stifel Buy → Hold $60 → $10
Nov-08-21Downgrade Canaccord Genuity Buy → Hold $72 → $12
Nov-08-21Downgrade Barclays Overweight → Equal Weight $50 → $11
Feb-12-24 09:55AM
Feb-07-24 09:20AM
Feb-06-24 07:00AM
04:50PM Loading…
Feb-01-24 04:50PM
Jan-30-24 10:01AM
Jan-18-24 11:13AM
Jan-08-24 07:00AM
Jan-05-24 07:00AM
Jan-02-24 07:00AM
Dec-15-23 07:06AM
Dec-02-23 07:08AM
Nov-29-23 11:30AM
07:00AM Loading…
Nov-07-23 07:00AM
Nov-01-23 03:03AM
Oct-31-23 07:25AM
Oct-30-23 08:15AM
Oct-16-23 12:39PM
Oct-05-23 11:38AM
Sep-29-23 09:00AM
Sep-22-23 12:02PM
Sep-15-23 05:00PM
11:30AM Loading…
Sep-08-23 11:30AM
Aug-21-23 07:43PM
Aug-19-23 07:40AM
Aug-18-23 04:05PM
Aug-11-23 03:30PM
Aug-10-23 08:13AM
Aug-09-23 08:50AM
Aug-03-23 04:15PM
Aug-02-23 07:00AM
Jun-09-23 09:02AM
Jun-02-23 11:31AM
May-25-23 05:00PM
May-23-23 07:00AM
May-08-23 01:31PM
May-04-23 05:38AM
May-03-23 08:15AM
Apr-27-23 10:03AM
Apr-26-23 10:02AM
Apr-19-23 07:00AM
Apr-18-23 06:53AM
Mar-23-23 11:30AM
Mar-16-23 05:25PM
Mar-15-23 11:52AM
Mar-14-23 05:53PM
Mar-09-23 11:30AM
Mar-01-23 07:00AM
Feb-27-23 07:00AM
Feb-08-23 02:13PM
Feb-07-23 08:35AM
Feb-02-23 07:00AM
Jan-31-23 07:00AM
Jan-24-23 04:02PM
Jan-19-23 07:56PM
Jan-18-23 04:54PM
Jan-13-23 10:15AM
Jan-04-23 12:16PM
Jan-03-23 04:02PM
Dec-31-22 07:01AM
Dec-01-22 07:00AM
Nov-08-22 07:00AM
Nov-04-22 03:57PM
Nov-03-22 08:15AM
Oct-27-22 07:00AM
Oct-20-22 09:40AM
Oct-18-22 03:01PM
Oct-04-22 09:40AM
Sep-30-22 10:20AM
Sep-12-22 01:38PM
Sep-11-22 06:30AM
Sep-10-22 09:00AM
Sep-01-22 07:00AM
Aug-30-22 01:17PM
Aug-19-22 04:05PM
Aug-11-22 09:45AM
Aug-10-22 04:20PM
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelly Thomas PatrickChief Financial OfficerFeb 16Sale15.623,01047,00980,350Feb 20 04:05 PM
Sherman Matthew LEVP & Chief Medical OfficerFeb 16Sale15.622,61540,840108,739Feb 20 04:06 PM
Martin Daniel C.Chief Commercial OfficerFeb 16Sale15.622,26735,40555,118Feb 20 04:05 PM
Pitman JamaSVP, Chief Development OfficerFeb 16Sale15.622,26735,40568,031Feb 20 04:05 PM
Kelly Thomas PatrickChief Financial OfficerJan 16Sale14.472,43535,23466,085Jan 18 04:15 PM
Sherman Matthew LEVP & Chief Medical OfficerJan 16Sale14.472,43535,23494,079Jan 18 04:15 PM
Pitman JamaSVP, Chief Development OfficerJan 16Sale14.471,62423,49950,573Jan 18 04:15 PM
Martin Daniel C.Chief Commercial OfficerJan 16Sale14.471,62423,49947,660Jan 18 04:15 PM
Hoerter Steven L.President and CEODec 13Sale15.3730,664471,21772,763Dec 14 04:05 PM
Kelly Thomas PatrickChief Financial OfficerDec 13Sale15.372,79242,90568,520Dec 14 04:05 PM
Sherman Matthew LEVP & Chief Medical OfficerDec 13Sale15.372,79242,90596,514Dec 14 04:05 PM
Martin Daniel C.Chief Commercial OfficerDec 13Sale15.371,72726,53949,284Dec 14 04:05 PM
Pitman JamaSee RemarksDec 13Sale15.371,66225,54052,197Dec 14 04:05 PM
Martin Daniel C.Chief Commercial OfficerNov 30Sale12.5717,801223,75545,435Dec 01 04:05 PM
Hoerter Steven L.President and CEOOct 30Sale12.0221,573259,25640,927Oct 31 04:09 PM
Sherman Matthew LEVP & Chief Medical OfficerOct 30Sale12.022,36028,36290,628Oct 31 04:11 PM
Kelly Thomas PatrickChief Financial OfficerOct 30Sale12.022,31627,83363,068Oct 31 04:09 PM
Martin Daniel C.Chief Commercial OfficerOct 30Sale12.021,40716,90962,884Oct 31 04:10 PM
Pitman JamaSee RemarksOct 30Sale12.021,40716,90948,283Oct 31 04:10 PM
Sherman Matthew LEVP & Chief Medical OfficerOct 02Sale12.682,94237,30584,744Oct 04 04:05 PM
Flynn Daniel LeeChief Scientific OfficerJun 16Sale14.401,65523,83557,158Jun 21 04:05 PM
Kelly Thomas PatrickChief Financial OfficerJun 16Sale14.401,65523,83557,140Jun 21 04:05 PM
Sherman Matthew LEVP & Chief Medical OfficerJun 16Sale14.401,65523,83587,686Jun 21 04:05 PM
Martin Daniel C.Chief Commercial OfficerJun 16Sale14.401,23817,82958,413Jun 21 04:05 PM
Pitman JamaSee RemarksJun 16Sale14.401,23817,82943,812Jun 21 04:05 PM
Friedman Franklin StuartDirectorJun 08Buy13.8810,000138,82810,000Jun 12 04:05 PM
Walsh Dennis LeoDirectorMay 10Buy13.8611,000152,41611,000May 12 04:05 PM
Hoerter Steven L.President and CEOMar 21Sale15.577,500116,7820Mar 23 04:05 PM